Related Experiment Video
Updated: Jun 26, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition
Ali M Nasser1, Lisa Melamed1, Ethan A Wetzel1
1Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Purpose:
Treatment paradigms for isocitrate dehydrogenase (IDH)-mutant gliomas are rapidly evolving. Although typically indolent and responsive to initial treatment, these tumors invariably recur at a higher grade and require salvage treatment. Homozygous deletion of the tumor suppressor gene CDKN2A/B frequently emerges at recurrence in these tumors, driving poor patient outcomes. We investigated the effect of CDK-Rb pathway blockade on IDH-mutant glioma growth in vitro and in vivo using CDK4/6 inhibitors (CDKi).
Experimental Design:
Cell viability, proliferation assays, and flow cytometry were used to examine the pharmacologic effect of two distinct CDKi, palbociclib and abemaciclib, in multiple patient-derived IDH-mutant glioma lines. Isogenic models were used to directly investigate the influence of CDKN2A/B status on CDKi sensitivity. Orthotopic xenograft tumor models were used to examine the efficacy and tolerability of CDKi in vivo.
Results:
CDKi treatment leads to decreased cell viability and proliferative capacity in patient-derived IDH-mutant glioma lines, coupled with enrichment of cells in the G1 phase. CDKN2A inactivation sensitizes IDH-mutant glioma to CDKi in both endogenous and isogenic models with engineered CDKN2A deletion. CDK4/6 inhibitor administration improves survival in orthotopically implanted IDH-mutant glioma models.
Conclusions:
IDH-mutant gliomas with deletion of CDKN2A/B are sensitized to CDK4/6 inhibitors. These results support the investigation of the use of these agents in a clinical setting.
Insights
CDK4/6 inhibitors show promise for treating recurrent IDH-mutant gliomas, especially those with CDKN2A/B deletion. This finding supports clinical trials for these targeted therapies.
Area of Science:
- Neuro-oncology
- Molecular oncology
- Cancer therapeutics
Background:
- Isocitrate dehydrogenase (IDH)-mutant gliomas are a significant challenge due to inevitable recurrence at a higher grade.
- Homozygous deletion of the tumor suppressor gene CDKN2A/B frequently emerges at recurrence, correlating with poor patient outcomes.
- Targeting the CDK-Rb pathway presents a potential therapeutic strategy for these aggressive tumors.
Purpose of the Study:
- To investigate the efficacy of CDK4/6 inhibitors (CDKi) in blocking the CDK-Rb pathway for IDH-mutant glioma growth.
- To determine the impact of CDKN2A/B deletion on CDKi sensitivity in IDH-mutant gliomas.
- To evaluate the therapeutic potential of CDKi in preclinical models of IDH-mutant glioma.
Main Methods:
- Utilized patient-derived IDH-mutant glioma cell lines for in vitro studies.
- Employed cell viability, proliferation assays, and flow cytometry to assess CDKi effects.
- Developed isogenic and orthotopic xenograft models to evaluate CDKi sensitivity and in vivo efficacy.
Main Results:
- CDKi treatment significantly reduced cell viability and proliferation in IDH-mutant glioma lines, inducing G1 cell cycle arrest.
- Loss of CDKN2A sensitized gliomas to CDKi, irrespective of endogenous or engineered deletion.
- In vivo administration of CDKi improved survival in orthotopic glioma xenograft models.
Conclusions:
- IDH-mutant gliomas with CDKN2A/B deletion exhibit enhanced sensitivity to CDK4/6 inhibitors.
- These findings provide a strong rationale for investigating CDKi in clinical settings for recurrent IDH-mutant gliomas.
- Targeted inhibition of CDK4/6 represents a promising therapeutic avenue for a subset of aggressive gliomas.
